Overview of HBV associated HBV-HIV coinfection

HIV and HBV infection share common routes of transmission, the prevalence of hepatitis B markers (anti-HBc, anti-hepatitis B core antibodies and/or HBs-Ag, the hepatitis B surface antigen) is up to 90% among HIV-infected patients.


ID Literature Title Group
1 10449493 Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.
Mutation
2 10679599 [Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients].
Mutation
3 10894274 Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee.
Mutation
4 12368144 [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Mutation
5 12853747 Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
Mutation
6 14760897 Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.
Mutation
7 15259898 In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Mutation
8 15339340 Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Mutation
9 15577546 Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Mutation
10 16218172 Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Mutation
11 16549970 Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Mutation
12 17086064 A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient.
Mutation
13 17224847 Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.
Mutation
14 17506609 Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.
Mutation
15 18167643 Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.
Mutation
16 18453854 The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
Mutation
17 18572746 Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Mutation
18 18624719 Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters.
Mutation
19 19098499 Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Mutation
20 19178592 Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Mutation
21 19301976 Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
Mutation
22 19475624 Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Mutation
23 19889143 Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals.
Mutation
24 19946588 Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report.
Mutation
25 20631103 Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana.
Mutation
26 20648600 High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Mutation
27 20655563 HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.
Mutation
28 21671883 Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
Mutation
29 21685546 HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
Mutation
30 21915864 Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.
Mutation
31 22156858 Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Mutation
32 22166560 Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico.
Mutation
33 22195774 Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.
Mutation
34 22422696 The perils of relying on anti-hepatitis B total core antibody in screening individuals infected with HIV.
Mutation
35 22459735 Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape.
Mutation
36 22592516 HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents.
Mutation
37 22860080 Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Mutation
38 22930502 Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
Mutation
39 23029487 Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa.
Mutation
40 23109450 Occult HBV infection among anti-HBc positive HIV-infected patients in apex referral centre, Eastern India.
Mutation
41 23465393 Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
Mutation
42 23487374 Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Mutation
43 23497042 Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.
Mutation
44 23892239 HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Mutation
45 23925707 Variability of the preC/C region of hepatitis B virus genotype A from a South African cohort predominantly infected with HIV.
Mutation
46 24444423 Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies.
Mutation
47 24587360 Molecular characterization of HBV strains circulating among the treatment-naive HIV/HBV co-infected patients of eastern India.
Mutation
48 24700252 HBV whole-genome mutation profile in HIV-1/HBV coinfected patients in a long-term follow-up study.
Mutation
49 24915064 Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.
Mutation
50 25449246 Genotyping and virological characteristics of hepatitis B virus in HIV-infected individuals in Sudan.
Mutation
51 25462190 Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance.
Mutation
52 25654813 High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Mutation
53 25786446 Hepatitis B e antigen and hepatitis B surface antigen seroclearance with the emergence of lamivudine-associated and core mutations following CD4 elevation in a patient with hepatitis B and HIV.
Mutation
54 25852125 Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Mutation
55 26384943 Occult hepatitis B virus infection and S gene escape mutants in HIV-infected patients after hepatitis B virus vaccination.
Mutation
56 26386408 Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
Mutation
57 26390290 Detection of Hepatitis B Virus (HBV) Genomes and HBV Drug Resistant Variants by Deep Sequencing Analysis of HBV Genomes in Immune Cell Subsets of HBV Mono-Infected and/or Human Immunodeficiency Virus Type-1 (HIV-1) and HBV Co-Infected Individuals.
Mutation
58 26419862 High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians.
Mutation
59 26764909 Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon.
Mutation
60 26890489 Complete genome analysis of hepatitis B virus in human immunodeficiency virus infected and uninfected South Africans.
Mutation
61 27061406 Overt and occult hepatitis B virus infection among treatment-naïve HIV-infected patients in Brazil.
Mutation
62 27245734 Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences.
Mutation
63 27354181 HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Mutation
64 27381922 HBsAg mutations related to occult hepatitis B virus infection in HIV-positive patients result in a reduced secretion and conformational changes of HBsAg.
Mutation
65 27769271 Serologic and genotypic characterization of hepatitis B virus in HIV-1 infected patients from South West and Littoral Regions of Cameroon.
Mutation
66 28376292 Hepatitis B virus sequencing and liver fibrosis evaluation in HIV/HBV co-infected Nigerians.
Mutation
67 28971485 Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients.
Mutation
68 29315352 Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
Mutation
69 29408943 Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Mutation
70 29660214 Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
Mutation
71 29948380 BCP/PC mutation prevalence and their association with HBV replication in HIV/HBV co-infected patients.
Mutation
72 30257068 Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.
Mutation
73 30368502 High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Mutation
74 30382563 Molecular characterization of hepatitis B virus in blood donors in Botswana.
Mutation
75 31566576 High frequency of drug resistance mutations in the HBV genome in ART-experienced HIV-coinfected patients in southwestern Nigeria.
Mutation
76 31622056 [Identification and molecular-genetic characteristics of the hepatitis B virus among HIV-infected patients in Arkhangelsk.]
Mutation
77 32545313 Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Mutation
78 32915862 Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.
Mutation
79 33245644 Optimization of the algorithm diagnosis chronic hepatitis B markers in patients with newly diagnosed HIV infection.
Mutation
80 33446224 Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria.
Mutation
81 33821807 Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study.
Mutation
Contents
Description
Group Note
  • Mutation Tag: literature about this virus mutation and click the eye icon to see detail mutation information in literature
  • VIS-cistrome Tag: literature associated this virus integration and click the eye icon to see detail information of 3 cistrome factors (histone modification, transcription factor binding site and chromatin accessibility)